DUS2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21801932	1.00	1/20
SCHEMBL19480001	0.82	1/20
SCHEMBL22847994	0.82	1/20
SCHEMBL19185507	0.80	1/20
SCHEMBL25829	0.78	1/20
SCHEMBL18862642	0.78	1/20
SCHEMBL14671647	0.77	1/20
SCHEMBL15877276	0.77	1/20
SCHEMBL17538496	0.77	1/20
SCHEMBL869098	0.77	1/20
SCHEMBL869099	0.77	1/20
SCHEMBL18427450	0.77	1/20
SCHEMBL18862766	0.77	1/20
SCHEMBL20325513	0.77	1/20
SCHEMBL4579463	0.76	1/20
SCHEMBL2944927	0.75	1/20
SCHEMBL2994889	0.75	1/20
SCHEMBL2994892	0.75	1/20
SCHEMBL15090850	0.74	1/20
SCHEMBL14148856	0.73	1/20

Clinical trials — most relevant to DUS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis	PHASE3	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate	PHASE1/PHASE2	UNKNOWN
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer	PHASE2	COMPLETED
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer	PHASE1	COMPLETED
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas	PHASE1	RECRUITING
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Danish Diabetes Birth Registry 2	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Identifying New Therapeutic Targets for Lupus Treatment	nan	COMPLETED
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)	nan	UNKNOWN
Mechanistic Studies of Teriflunomide in RRMS	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction	nan	COMPLETED
miRNA as a Growth Plate Marker After GH	nan	UNKNOWN
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
Timisnar - Biomarkers Substudy (Timisnar-mirna)	nan	UNKNOWN
Validation of Gene Expression Markers of Renal Allograft Functional Decline	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Molecular Mechanisms Underlying Prostate Cancer Disparities	nan	COMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Role of Piwi-protein Interacting RNA, miRNA-194 and Amino Acids in Patients With Prostate Cancer	nan	UNKNOWN
New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy	nan	COMPLETED
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DUS2 binder may also engage these)

Protein	Name	Similarity
Q9D7B1	—	0.995	Q9D7B1 →
Q9NVE7	—	0.957	Q9NVE7 →
Q5R5F8	—	0.957	Q5R5F8 →
Q6AXQ0	—	0.956	Q6AXQ0 →
Q4R4U1	—	0.955	Q4R4U1 →
AKR7A2	Aflatoxin B1 aldehyde reductase member 2	0.953	landscape →
Q5NVN7	—	0.951	Q5NVN7 →
A2VE14	—	0.950	A2VE14 →
Q9R1T2	—	0.950	Q9R1T2 →
Q96G46	—	0.949	Q96G46 →
SAE1	SUMO-activating enzyme subunit 1	0.949	landscape →
O75648	—	0.947	O75648 →
Q923S8	—	0.947	Q923S8 →
Q91YD4	—	0.946	Q91YD4 →
TRPM2	Transient receptor potential cation channel subfamily M member 2	0.945	landscape →
Q9D880	—	0.943	Q9D880 →
TIMM50	Mitochondrial import inner membrane translocase subunit TIM50	0.943	landscape →
Q5I0D5	—	0.943	Q5I0D5 →
Q64380	—	0.942	Q64380 →
Q29081	—	0.942	Q29081 →
Q5I0K3	—	0.941	Q5I0K3 →
Q8CIW5	—	0.941	Q8CIW5 →
Q6DC64	—	0.941	Q6DC64 →
Q9DAT5	—	0.941	Q9DAT5 →
P20595	—	0.941	P20595 →
E9PTA2	—	0.940	E9PTA2 →
Q4ZHR9	—	0.940	Q4ZHR9 →
Q5RAJ8	—	0.940	Q5RAJ8 →
Q3SZB3	—	0.939	Q3SZB3 →
Q9H008	—	0.939	Q9H008 →